NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $5.25 -0.03 (-0.57 %) (As of 07/18/2018 04:00 PM ET)Previous Close$5.20Today's Range$5.10 - $5.2552-Week Range$4.85 - $9.95Volume610,700 shsAverage Volume705,891 shsMarket Capitalization$301.43 millionP/E Ratio-8.08Dividend YieldN/ABeta2.24 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of various therapeutic products to treat inflammatory and fibrotic diseases. The company's lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug that is in Phase III clinical trials for the treatment of systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. Corbus Pharmaceuticals Holdings, Inc. was founded in 2009 and is based in Norwood, Massachusetts. Receive CRBP News and Ratings via Email Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:CRBP CUSIPN/A Webwww.corbuspharma.com Phone617-963-0100 Debt Debt-to-Equity RatioN/A Current Ratio7.25 Quick Ratio7.25 Price-To-Earnings Trailing P/E Ratio-8.08 Forward P/E Ratio-6.18 P/E GrowthN/A Sales & Book Value Annual Sales$2.44 million Price / Sales122.94 Cash FlowN/A Price / CashN/A Book Value$1.04 per share Price / Book5.05 Profitability EPS (Most Recent Fiscal Year)($0.65) Net Income$-32,420,000.00 Net MarginsN/A Return on Equity-76.01% Return on Assets-64.57% Miscellaneous Employees47 Outstanding Shares57,140,000Market Cap$301.43 Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions What is Corbus Pharmaceuticals' stock symbol? Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP." How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) posted its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.11. The biopharmaceutical company earned $0.95 million during the quarter, compared to analyst estimates of $6.25 million. View Corbus Pharmaceuticals' Earnings History. What price target have analysts set for CRBP? 3 analysts have issued 1 year price targets for Corbus Pharmaceuticals' shares. Their predictions range from $20.00 to $32.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $25.3333 in the next twelve months. This suggests a possible upside of 382.5% from the stock's current price. View Analyst Ratings for Corbus Pharmaceuticals. What is the consensus analysts' recommendation for Corbus Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Corbus Pharmaceuticals' key competitors? Some companies that are related to Corbus Pharmaceuticals include Athenex (ATNX), Zai Lab (ZLAB), Eagle Pharmaceuticals (EGRX), Tricida (TCDA), Retrophin (RTRX), Endocyte (ECYT), Esperion Therapeutics (ESPR), Reata Pharmaceuticals (RETA), Intra-Cellular Therapies (ITCI), Wave Life Sciences (WVE), Revance Therapeutics (RVNC), Apellis Pharmaceuticals (APLS), Vanda Pharmaceuticals (VNDA), OptiNose (OPTN) and Flexion Therapeutics (FLXN). Who are Corbus Pharmaceuticals' key executives? Corbus Pharmaceuticals' management team includes the folowing people: Dr. Yuval Cohen, CEO & Director (Age 43)Dr. Mark A. Tepper Ph.D., Co-Founder, Pres & Chief Scientific Officer (Age 61)Dr. Barbara White M.D., Chief Medical Officer (Age 68)Mr. Sean F. Moran CPA, MBA, CFO & Principal Accounting Officer (Age 60)Scott Constantine M.S., Director of Clinical Research & Operations Has Corbus Pharmaceuticals been receiving favorable news coverage? News articles about CRBP stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of 0.24 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 48.05 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. Who are Corbus Pharmaceuticals' major shareholders? Corbus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Fox Run Management L.L.C. (0.05%). Company insiders that own Corbus Pharmaceuticals stock include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals. Which major investors are buying Corbus Pharmaceuticals stock? CRBP stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Corbus Pharmaceuticals' stock price today? One share of CRBP stock can currently be purchased for approximately $5.25. How big of a company is Corbus Pharmaceuticals? Corbus Pharmaceuticals has a market capitalization of $301.43 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe. How can I contact Corbus Pharmaceuticals? Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected] MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 214 (Vote Outperform)Underperform Votes: 115 (Vote Underperform)Total Votes: 329MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?